OXALIPLATIN INJECTION
As listed in the register: OXALIPLATIN INJECTION, USP
5 mg · solution
- Prescription only
- Cancer treatments and immune-system medicines
- Active substance
- Oxaliplatin
- Made by
- Fresenius Kabi Canada Ltd
- Source
- Official label
Quoted from the official source. Not yet reviewed by Mediclarum — the leaflet in your pack is authoritative.
What it is for
Mediclarum has not yet retrieved and stored the official label for this product, so none of its text is shown here. Open the official leaflet
How it works
From the US prescribing label for the same active substance (Oxaliplatin). It describes the substance, not this exact product.
Oxaliplatin undergoes nonenzymatic conversion in physiologic solutions to active derivatives via displacement of the labile oxalate ligand.
Several transient reactive species are formed, including monoaquo and diaquo DACH platinum, which covalently bind with macromolecules.
The remaining 85% is rapidly distributed into tissues or eliminated in the urine.
Quoted from the prescribing label, sections “Mechanism of Action” and “Pharmacokinetics”. DailyMed · 2026-08-24
Safety of the active substance
From the US prescribing label for the same active substance (Oxaliplatin). It describes the substance, not this exact product.
WARNING: HYPERSENSITIVITY REACTIONS, INCLUDING ANAPHYLAXIS Serious and fatal hypersensitivity adverse reactions, including anaphylaxis, can occur with oxaliplatin within minutes of administration and during any cycle.
- Oxaliplatin is contraindicated in patients with a history of a hypersensitivity reaction to oxaliplatin or other platinum-based drugs.
- Reactions have included anaphylaxis [see Warnings and Precautions (5.1) ].
- History of hypersensitivity reaction to oxaliplatin or other platinum-based drugs.
The most common adverse reactions in patients with stage II or III colon cancer receiving adjuvant treatment were peripheral sensory neuropathy, neutropenia, thrombocytopenia, anemia, nausea, increase in transaminases and alkaline phosphatase, diarrhea, emesis, fatigue and stomatitis.
Quoted from the US prescribing label for the same active substance. Your own pack’s leaflet is the authority for your product. DailyMed
Same active substance, strength and form in other countries
Matched on active substance, strength and kind of form only. This is not a statement that the products are equivalent or interchangeable: other ingredients, release and approved uses can differ — ask a pharmacist before swapping.
Medicine passport: one printable page to show a pharmacist abroad
United StatesNo exact match for this strength and form
SpainNo exact match for this strength and form
NetherlandsNo exact match for this strength and form
SwitzerlandNo exact match for this strength and form
Details
| Made by | Fresenius Kabi Canada Ltd |
|---|---|
| Active substance | Oxaliplatin |
| Used in | Cancer treatments and immune-system medicines |
| Strength | 5 mg |
| Form | solution |
| Classification | L01XA03 · Cancer treatments and immune-system medicines |
| Route | intravenous |
| Dispensing (as stated by the register) | PRESCRIPTION |
| Status | Marketed |
| Marketed | Yes, according to the register |
| Name in the register | OXALIPLATIN INJECTION, USP |
| DIN | 02457423 |
| DPD drug code | 94448 |
Source: Drug Product Database · 2026-09-30 · not reviewed by a clinician
Contains information licensed under the Open Government Licence – Canada. Reuse terms: Open Government Licence – Canada.
Other strengths and forms
8 products are sold under this name. Grouped by form; a number on a strength means several companies make it.
- solution8 products
5 mg8
5 mg · 8 companies
Same active substance
These contain the same substance. That does not mean one can replace another — ask a pharmacist.